MENLO PARK, Calif., Sept. 16, 2021 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (NASDAQ: SGHT) today announced that it filed a lawsuit in the United States District Court in Delaware against Ivantis, Inc. for infringement of U.S. Patent Numbers 8,287,482, 9,370,443, 9,486,361, and 10,314,742. These patents describe and claim devices and methods for reducing intraocular pressure in the eye.<\/p>\n
Sight Sciences\u2019 complaint seeks an injunction to prevent the infringing manufacture, use and sale of the Hydrus\u00ae Microstent, along with money damages for past infringement. \u201cWe filed this lawsuit to protect and defend our commercial, market and intellectual property leadership positions within the field of canalicular glaucoma surgery,\u201d said Paul Badawi, co-founder and CEO of Sight Sciences, and co-inventor of the patents-in-suit.<\/p>\n
Since 2006, Sight Sciences has been innovating in circumferential glaucoma surgery (implantable and non-implantable). Its extensive patent portfolio covers many approaches to circumferential glaucoma surgery, including, but not limited to, canalicular scaffolding implants, canaloplasty and trabeculotomy devices and methods, and methods of drug delivery within the canal.<\/p>\n
About Sight Sciences<\/strong> OMNI\u00ae<\/sup> and TearCare\u00ae<\/sup> are registered trademarks of Sight Sciences. Media contact: Investor contact: Sight Sciences Seeks Injunction Related to Hydrus\u00ae Microstent\u2019s Infringement<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[6],"tags":[],"class_list":["post-790","post","type-post","status-publish","format-standard","hentry","category-news"],"acf":[],"yoast_head":"\n
\nSight Sciences is an eyecare technology company focused on developing and commercializing innovative solutions intended to transform standards of care and improve patients\u2019 lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world\u2019s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company\u2019s OMNI Surgical System is a minimally invasive glaucoma surgery (MIGS) device indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma (POAG), the world\u2019s leading cause of irreversible blindness. The Company\u2019s TearCare System is commercially available today as a wearable, office-based thermal eyelid technology that enables the controlled application of localized heat to the eyelids. TearCare is in development for the treatment of the signs and symptoms of evaporative dry eye, the primary form of dry eye disease which is the number one reason for a patient visit to an eyecare provider. For more information, visit www.sightsciences.com.<\/p>\n
\n\u00a9 2021 Sight Sciences. All rights reserved.<\/p>\n
\nShay Smith
\nHealth+Commerce
\n707.971.9779
\nshay@healthandcommerce.com<\/p>\n
\nPhilip Taylor
\nGilmartin Group
\n415.937.5406
\nInvestor.Relations@Sightsciences.com<\/p>\n","protected":false},"excerpt":{"rendered":"